Subscribe To
LIAN / Why LianBio Stock Is Shooting Through the Roof This Week
LIAN News
By The Motley Fool
October 27, 2023
Why LianBio Stock Is Shooting Through the Roof This Week
LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianB more_horizontal
By InvestorPlace
October 24, 2023
Why Is LianBio (LIAN) Stock Up 130% Today?
Shares of LianBio (NASDAQ: LIAN ) — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inf more_horizontal
By The Motley Fool
October 24, 2023
Why LianBio Stock Is Skyrocketing Today
LianBio entered into a deal to give Bristol Myers Squibb exclusive rights for mavacemten in China and other Asian markets. The small drugmaker will re more_horizontal
By GlobeNewsWire
June 1, 2023
LianBio to Participate in Upcoming Investor Conferences
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovativ more_horizontal
By Zacks Investment Research
December 20, 2022
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is elig more_horizontal
By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal
By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal
By Seeking Alpha
March 2, 2022
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market more_horizontal